# Signals Article on Putative Target P36896 for Systemic Sclerosis
Background
The protein encoded by the putative target P36896 has emerged as a candidate of interest in the study of systemic sclerosis (SSc), a complex autoimmune disorder characterized by fibrosis of the skin and internal organs, along with vascular abnormalities. Preliminary findings suggest that P36896 may play a role in the fibrotic processes and immune dysregulation associated with systemic sclerosis, indicating its potential as a therapeutic target. Given the multifactorial nature of this disease, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.Data-mining rationale
Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "systemic sclerosis" against 363 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:P36896 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in systemic sclerosis and underscores the need for further exploration.Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of P36896 in the context of systemic sclerosis. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in this autoimmune condition.Reasoning for further validation
To substantiate the potential role of P36896 in systemic sclerosis, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including P36896, by quantitative PCR (qPCR) in an independent cohort of systemic sclerosis patients to confirm expression patterns. 3. Investigate the tissue specificity of P36896 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in fibrotic tissues and immune cells. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize P36896 within known biological pathways related to fibrosis and immune responses in systemic sclerosis. 5. If validation is achieved, assess the druggability of P36896 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.References
- [UniProt: P36896](https://www.uniprot.org/uniprot/P36896)
- [UniProt: Q9BUI4](https://www.uniprot.org/uniprot/Q9BUI4)
- [UniProt: P01911](https://www.uniprot.org/uniprot/P01911)
- [UniProt: Q13568](https://www.uniprot.org/uniprot/Q13568)
- [UniProt: Q9UHD2](https://www.uniprot.org/uniprot/Q9UHD2)
- [NCBI GEO Accession GDS:200286162](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200286162)
- [NCBI GEO Accession GDS:200287422](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200287422)
- [NCBI GEO Accession GDS:200267908](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200267908)
- [NCBI GEO Accession GDS:200291167](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200291167)
- [NCBI GEO Accession GDS:200201405](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200201405)